Urgent.News

What's breaking now, across thousands of outlets.

Business

Solstice Oncology secures 225 million series A for immuno oncology therapy

Harbour BioMed partner Solstice Oncology secured 225 million in Series A financing to advance porustobart a novel neoadjuvant immuno oncology therapy targeting diverse cancer treatments

We haven't written up this one. Vietnam Investment Review has the full story — the link below goes straight to it.

Read the original at vir.com.vn →

More in Business

More from Thursday 10 September →